Biodesix (NASDAQ:BDSX) Director Purchases $92,514.68 in Stock

Key Points

• Jack Schuler, a director at Biodesix, acquired 15,317 shares of the company's stock at an average price of $6.04 per share, increasing his position by 1.26% to a total of 1,235,644 shares.
• Biodesix reported a quarterly loss of ($1.60) EPS, missing analysts' expectations, but exceeded revenue estimates with $20.02 million in revenue.
• Research analysts show a mixed sentiment on Biodesix, with four rating it as a Buy and an average target price of $32.50, despite one recent downgrade to a "sell" rating.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack W. Schuler purchased 15,317 shares of the company's stock in a transaction on Wednesday, September 17th. The stock was bought at an average price of $6.04 per share, for a total transaction of $92,514.68. Following the completion of the purchase, the director directly owned 1,235,644 shares of the company's stock, valued at $7,463,289.76. The trade was a 1.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Biodesix Stock Up 0.3%

Biodesix stock traded up $0.02 during mid-day trading on Monday, hitting $7.15. The company had a trading volume of 58,910 shares, compared to its average volume of 341,148. Biodesix, Inc. has a 1 year low of $3.44 and a 1 year high of $36.00. The company has a debt-to-equity ratio of 41.11, a quick ratio of 2.14 and a current ratio of 2.14. The business has a fifty day moving average of $7.99 and a 200 day moving average of $8.82.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.40) by ($0.20). The company had revenue of $20.02 million during the quarter, compared to analysts' expectations of $18.47 million. Biodesix had a negative net margin of 53.66% and a negative return on equity of 269.67%. Biodesix has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Biodesix, Inc. will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Biodesix

Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd lifted its holdings in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock worth $58,000 after purchasing an additional 102,494 shares during the period. Birchview Capital LP lifted its holdings in shares of Biodesix by 2.8% during the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company's stock worth $3,586,000 after purchasing an additional 154,937 shares during the period. Monashee Investment Management LLC lifted its holdings in shares of Biodesix by 15.7% during the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company's stock worth $2,532,000 after purchasing an additional 549,121 shares during the period. Blair William & Co. IL lifted its holdings in shares of Biodesix by 33.3% during the first quarter. Blair William & Co. IL now owns 124,100 shares of the company's stock worth $78,000 after purchasing an additional 31,000 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Biodesix by 20.2% during the fourth quarter. Millennium Management LLC now owns 198,671 shares of the company's stock worth $304,000 after purchasing an additional 33,329 shares during the period. 20.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BDSX has been the topic of several recent analyst reports. Canaccord Genuity Group set a $20.00 price target on shares of Biodesix and gave the company a "buy" rating in a research note on Friday. Wall Street Zen upgraded shares of Biodesix to a "sell" rating in a research report on Saturday, September 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $32.50.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.